Unlock the full value of your oncology innovation !
MATWIN is an accelerator program aiming at challenging and maximizing innovation transfer potential exclusively on oncology. Through a support course over 3 or 6 months, candidates will have access to support through expertise, coaching/mentoring and a qualified network of partners likely to help them accelerate the development of their project.
This year MATWIN is partnering with the Paris Saclay Cancer Cluster in order to increase the added value of the support offered through the program and capitalize on the synergies of the offers and networks of these two organizations.
The program is open to European candidates (academic team or start-up) developing an innovative R&D product or service in oncology. Consult different support paths’ details below.
You can also access MATWIN’s expertise throughout the year (see “Tailor-made service offers” section)
START program (6 months)
application by October 31, 2024
Restricted to academic teams or young startups needing to optimize their project's strenght and having only preclinical results available before the regulatory tox for therapeutic innovations or ante validation for diagnostic tests
1/ Submit application
October 31, 2024
2/ Preselection pitch
November 2024
3/ Written jury member review
December 2024
4/ 2 personalized coaching sessions + 1h Board mentoring
January-April 2025
5/ MATWIN International Board interview
May 2025
GROW program (3 months)
application by January 31, 2024
Restricted to startups with preclinical results of regulatory tox or a first clinical study (Phase 1)
for therapeutic innovations or a validated test for diagnostic tests
1/ Submit application then sent to MATWIN Board
January 31, 2025
2/ 1 personalized coaching session
+ 1h Board mentoring
March-April 2025
3/ MATWIN International Board interview
May 2025
Before applying, please read the MATWIN charter listing the rights and obligations of MATWIN and candidates
To apply
Consult the FAQs in the text of the call for applications.
Before submitting any application, it is essential to contact MATWIN to jointly assess the opportunity.
Eligibility requirements
- Innovative R&D project (service offers (e.g. CRO services) will be automatically discarded)
- Original and innovative target, MoA, marker/biomarker, technological approach
- Strength of intellectual property (patent application filed or pending)
- Maturity: if product: established preclinical in vivo (or early clinical) POC, MoA, SAR, associated biomarker if diagnostic test: selectivity, specificity, impact on the therapeutic choice...
Program advantages
- Become familiar with market expectations by accessing the expertise of an international network of peers, pharmas / biotechs / investors
- Optimize the industrial structuring of the project and enhance its development potential
- Obtain development plan validation guidelines (clinical positioning, indications, milestones, etc.)
- Become investor-ready while reducing their go-to-market risk
- Increase the project’s, visibility and accelerate its promotion for the benefit of patients